Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Antibiotic Accelerator From BARDA Nears Investment Stage

This article was originally published in The Pink Sheet Daily

Executive Summary

Federal funding could pay to help early antibiotic discovery efforts with 'fragile' pipeline still struggling.

You may also be interested in...



FDA Worries About Off-Label Use, Stewardship With Limited-Population Approval Pathway

FDA asks groups how it can help ensure prescribing is limited for products approved under proposed new pathway, but several say, other than labeling, it may be out of the agency’s hands.

Pfizer’s COVID-19 Vaccine Data In Young Children Could Place US FDA In Awkward Position Again

The agency is considering how to move forward as Pfizer studies a third shot after missing an efficacy endpoint in children age 2 to 5.

Califf Confident Public Trust In US FDA Will Be Rebuilt

Commissioner nominee strikes an optimistic note as former FDA heads raise concerns about the decrease in agency credibility during the pandemic.

Topics

Related Companies

UsernamePublicRestriction

Register

PS079504

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel